Trouw Nutrition Research and Development, PO Box 299, 3800 AG, Amersfoort, the Netherlands.
Trouw Nutrition Research and Development, PO Box 299, 3800 AG, Amersfoort, the Netherlands.
J Dairy Sci. 2019 Jul;102(7):6056-6064. doi: 10.3168/jds.2018-15754. Epub 2019 May 10.
Hypocalcemia is a common postpartum condition in dairy cows, which negatively affects health and production. Intravenous Ca infusions are commonly included in calving protocols to prevent or mitigate the effect of hypocalcemia in multiparous cows. Thus, we sought to contrast the effect of intravenous Ca infusion against voluntary oral Ca intake on Ca metabolism. Serum total Ca (tCa) and whole-blood ionized Ca (iCa) were monitored in 24 multiparous Holstein cows after parturition. Precalving diets were formulated with a positive dietary cation-anion difference of 172 mEq/kg of DM and contained 4.1 g of Ca/kg of DM. At parturition, cows were blocked by calving sequence and calcemic status as either normocalcemic (cutoff threshold of iCa ≥1.10 mmol/L) or hypocalcemic (cutoff threshold of iCa <1.10 mmol/L). Cows in each block were randomly assigned to 1 of 2 treatments: either an oral source of Ca (Ca-Oral; n = 12) or an intravenous source of Ca (Ca-IV; n = 12). Cows in the Ca-Oral group were offered a 20-L commercial Ca suspension (48 g of Ca) for voluntary consumption. The supplement contained Ca carbonate, Ca formate, Ca propionate, and other minerals and vitamins (Farm-O-San Reviva, Trouw Nutrition, Amersfoort, the Netherlands). Cows in the Ca-IV group received a 450-mL intravenous Ca solution (13 g of Ca) that contained 298 mg/mL of Ca gluconate, 33 mg/mL of magnesium chloride, and 82 mg/mL of boric acid (AmosCAL, Kommer-Biopharm BV, Heiloo, the Netherlands). Both treatments were initiated within 25 ± 10 min after calving. The oral Ca suspension was offered to cows in a 25-L bucket and was available for 10 min. All cows in the Ca-Oral group voluntarily consumed the entire 20 L of the Ca suspension within 5 min. Blood samples for Ca analyses were collected at 0 (before treatment initiation), 1, 3, 10, and 18 h relative to treatment, and at 0700 and 1900 h for the next 2 consecutive days, to represent the 24-, 36-, 48-, and 60-h sampling time points. In Ca-IV cows, both iCa and tCa concentrations peaked at 1 h (1.54 mmol/L for iCa and 2.85 mmol/L for tCa) and declined to a nadir at 24 h following treatment initiation (0.94 mmol/L for iCa and 1.74 mmol/L for tCa). Although whole-blood iCa and serum tCa were higher at 1 and 3 h in Ca-IV cows, concentrations of iCa were greater for Ca-Oral cows at 18, 24, and 36 h and for tCa at 24 and 36 h. Our data indicate that intravenous Ca infusion immediately induced a state of hypercalcemia followed by lower whole-blood iCa and serum tCa concentrations 24 h later compared with oral Ca.
低钙血症是奶牛产后的一种常见病症,会对奶牛的健康和生产产生负面影响。静脉注射钙通常包含在产犊方案中,以预防或减轻高产奶牛的低钙血症的影响。因此,我们旨在对比静脉注射钙与口服钙对钙代谢的影响。在产后 24 头荷斯坦奶牛中监测血清总钙(tCa)和全血离子钙(iCa)。产前饲料的阳离子-阴离子差值为正 172 毫当量/千克 DM,且含有 4.1 克钙/千克 DM。在产犊时,根据 iCa 的钙含量(正常 iCa 阈值≥1.10 毫摩尔/升)和低钙血症状态(正常 iCa 阈值<1.10 毫摩尔/升)将奶牛分为正常钙血症(n = 12)或低钙血症(n = 12)。每个分组中的奶牛随机分配到 2 种处理之一:口服钙源(Ca-Oral;n = 12)或静脉注射钙源(Ca-IV;n = 12)。口服钙组的奶牛提供了 20 升商业钙悬浮液(48 克钙)供自愿饮用。该补充剂含有碳酸钙、甲酸盐、丙酸盐和其他矿物质和维生素(Farm-O-San Reviva,Trouw Nutrition,Amersfoort,荷兰)。静脉注射钙组的奶牛接受了 450 毫升静脉注射钙溶液(13 克钙),其中含有 298 毫克/毫升的葡萄糖酸钙、33 毫克/毫升的氯化镁和 82 毫克/毫升的硼酸(AmosCAL,Kommer-Biopharm BV,Heiloo,荷兰)。两种处理均在产后 25 ± 10 分钟内开始。口服钙悬浮液在一个 25 升的桶中提供给奶牛,持续 10 分钟。口服钙组的所有奶牛在 5 分钟内自愿饮用了 20 升钙悬浮液。在治疗开始后 0(开始治疗前)、1、3、10 和 18 小时以及接下来的 2 天 0700 和 1900 小时采集血液样本进行钙分析,以代表 24、36、48 和 60 小时的采样时间点。在静脉注射钙组中,iCa 和 tCa 浓度在 1 小时(iCa 为 1.54 毫摩尔/升,tCa 为 2.85 毫摩尔/升)达到峰值,并在治疗开始后 24 小时下降到最低点(iCa 为 0.94 毫摩尔/升,tCa 为 1.74 毫摩尔/升)。尽管静脉注射钙组的 iCa 和 tCa 在 1 和 3 小时较高,但口服钙组的 iCa 在 18、24 和 36 小时和 tCa 在 24 和 36 小时更高。我们的数据表明,与口服钙相比,静脉注射钙立即引起高钙血症,随后在 24 小时后导致全血 iCa 和血清 tCa 浓度降低。